These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29656449)

  • 1. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
    Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
    Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
    Brennan AT; Maskew M; Ive P; Shearer K; Long L; Sanne I; Fox MP
    J Int AIDS Soc; 2013 Nov; 16(1):18794. PubMed ID: 24256692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?
    Brennan AT; Davies MA; Bor J; Wandeler G; Stinson K; Wood R; Prozesky H; Tanser F; Fatti G; Boulle A; Sikazwe I; Wool-Kaloustian K; Yuannoutsos C; Leroy V; de Rekeneire N; Fox MP
    AIDS; 2017 Jan; 31(1):147-157. PubMed ID: 27776039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
    Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
    AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa.
    Onoya D; Hirasen K; van den Berg L; Miot J; Long LC; Fox MP
    Drug Saf; 2018 Dec; 41(12):1343-1353. PubMed ID: 30043384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
    Njuguna C; Orrell C; Kaplan R; Bekker LG; Wood R; Lawn SD
    PLoS One; 2013; 8(5):e63596. PubMed ID: 23717451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
    Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A
    PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa.
    Brennan AT; Jamieson L; Crowther NJ; Fox MP; George JA; Berry KM; Stokes A; Maskew M; Sanne I; Long L; Cassim N; Rosen S
    PLoS One; 2018; 13(10):e0204020. PubMed ID: 30281618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
    Brennan AT; Shearer K; Maskew M; Long L; Sanne I; Fox MP
    Trop Med Int Health; 2014 May; 19(5):490-8. PubMed ID: 24589363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
    Abgrall S; Ingle SM; May MT; Costagliola D; Mercie P; Cavassini M; Reekie J; Samji H; Gill MJ; Crane HM; Tate J; Sterling TR; Antinori A; Reiss P; Saag MS; Mugavero MJ; Phillips A; Manzardo C; Wasmuth JC; Stephan C; Guest JL; Gomez Sirvent JL; Sterne JA;
    AIDS; 2013 Mar; 27(5):803-13. PubMed ID: 23719350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
    Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
    Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
    Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
    Shearer K; Fox MP; Maskew M; Berhanu R; Long L; Sanne I
    PLoS One; 2013; 8(8):e71719. PubMed ID: 23940782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.
    Technau KG; Schomaker M; Kuhn L; Moultrie H; Coovadia A; Eley B; Rabie H; Wood R; Cox V; Vizcaya LS; Muchiri E; Davies MA;
    Pediatr Infect Dis J; 2014 Jun; 33(6):617-22. PubMed ID: 24378944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
    van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T
    Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
    Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
    AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
    Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
    Steegen K; Levin L; Ketseoglou I; Bronze M; Papathanasopoulos MA; Carmona S; Stevens W
    PLoS One; 2014; 9(5):e97067. PubMed ID: 24816790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.